EQS-Adhoc: Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

2015-06-29 / 14:38 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement.

=--------------------------------------------------------------------

Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

Schlieren (Zurich), Switzerland, 29 June 2015 - Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders' Meeting 2015.

The Annual Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 71 shareholders. 22,475,425 shares or 20.81% of a total of 108,015,276 shares were represented.

For further information, please contact:

Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 e-mail: harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++ Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=NYQATQMSSL Document title: Cytos_AGM

=--------------------------------------------------------------------

2015-06-29 News transmitted by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

=--------------------------------------------------------------------

Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service =-------------------------------------------------------------------- 373069 2015-06-29 (END) Dow Jones Newswires

   June 29, 2015 08:38 ET (12:38 GMT)- - 08 38 AM EDT 06-29-15